Physician profile
Joyce R Lines
NPI 1649270588
$3,742.82
in general payments reported to CMS, 2019-2025
29 companies · $414 in 2025
The $414 reported for 2025 was more than what 76% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,005 · 2020: $244 · 2021: $641 · 2022: $425 · 2023: $562 · 2024: $452 · 2025: $414.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,328 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,328.31 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $700.00 | 2019 | |
| Abbvie INC. | $696.64 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $300.29 | 2021-2024 | |
| Astellas Pharma US INC | $298.26 | 2019-2025 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $203.11 | 2019-2025 | |
| Therapeuticsmd, INC. | $175.19 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $170.65 | 2022-2023 | Quviviq |
| Biogen, INC. | $139.77 | 2025 | Zurzuvae |
| Coopersurgical, INC. | $122.67 | 2019-2024 | Paragard T 380a, Paragard T 380a |
| Exeltis, USA INC. | $117.65 | 2021-2024 | Slynd |
| Pfizer INC. | $112.46 | 2022-2024 | |
| Myovant Sciences INC. | $111.41 | 2021-2022 | |
| Octapharma USA, INC. | $81.11 | 2025 | Fibryga |
| Daiichi Sankyo INC. | $73.02 | 2024 | Injectafer |
| Hologic Sales and Service, LLC | $64.77 | 2019-2024 | Aptima, Myosure Tissue Removal Device, Thinprep 2000 Processor |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $56.23 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $54.31 | 2024 | Gardasil 9, Gardasil |
| Agile Therapeutics, INC. | $37.61 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $36.91 | 2023-2024 | Myfembree |
| Medtronic, INC. | $27.83 | 2022 | |
| Exact Sciences Corporation | $25.53 | 2024 | Cologuard Collection Kit |
| Solventum Corporation | $23.64 | 2024 | Prevena |
| Davol INC. | $22.84 | 2024 | Arista Ah Flexitip |
| Biohaven Pharmaceutical Holding Company LTD. | $20.20 | 2022 | |
| Minerva Surgical, INC | $18.53 | 2022 | |
| Roche Diagnostics Corporation | $14.20 | 2019 | |
| Allergan, INC. | $13.63 | 2020 | |
| Alexion Pharmaceuticals, INC. | $13.13 | 2023 | Ultomiris |
| Organon LLC | $11.23 | 2023 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joyce Lines listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.